India’s patent office granted Pfizer Inc. a patent for its best-selling pneumonia vaccine PCV13 vaccine, marketed as Prevnar 13, barring other companies from making cheaper generic versions of the injection and allowing the company exclusive rights to sell it in the country of 1.3bn people until 2026.
Humanitarian group Médecines Sans Frontières, which had opposed Pfizer’s patent bid, said it feared the decision indicated a watering down...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
